• 1
    Flegal, K. M., Carroll, M. D., Ogden, C. L., Johnson, CL. (2002) Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 288: 17231727.
  • 2
    World Health Organization. (2003) Obesity Epidemic Puts Millions at Risk from Related Diseases: Press Release WHO/46, June 12, 1997. http:www.who.intarchivesinf-pr-1997enpr97-46.html (Accessed August 13).
  • 3
    Resnick, H. E., Valsania, P., Halter, J. B., Lin, X. (2000) Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Community Health. 54: 596602.
  • 4
    Wilson, P. W., D'Agostino, R. B., Sullivan, L., Parise, H., Kammel, WB. (2002) Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 162: 18671872.
  • 5
    Brown, C. D., Higgins, M., Donato, K. A., et al (2000) Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 8: 605619.
  • 6
    Hochberg, M. C., Lethbridge-Cejku, M., Scott, W. W., Jr, Reichle, R., Plato, C. C., Tobin, J. D. (1995) The association of body weight, body fatness and body fat distribution with osteoarthritis of the knee: data from the Baltimore Longitudinal Study of Aging. J Rheumatol. 22: 488493.
  • 7
    Calle, E. E., Thun, M. J., Petrelli, J. M., Rodriguez, C., Heath, C. W. (1999) Body mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 341: 10971105.
  • 8
    Yanovski, S. Z., Yanovski, JA. (2002) Obesity. N Engl J Med. 346: 591602.
  • 9
    Knowler, W. C., Barrett-Connor, E., Fowler, S. E., et al (2002) Diabetes Prevention Program Research Group: reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346: 393403.
  • 10
    NIH Technology Assessment Conference Panel. (1993) Methods for voluntary weight loss and control. Ann Intern Med. 119: 764770.
  • 11
    Sjöström, L., Rissanen, L., Andersen, T., et al (1998) Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients: European Multicentre Orlistat Study Group. Lancet. 352: 167172.
  • 12
    Apfelbaum, M., Vague, P., Ziegler, O., Hanotin, C., Thomas, F., Leutenegger, E. (1999) Long-term maintenance of weight loss after a very-low-calorie diet: a randomized trial of the efficacy and tolerability of sibutramine. Am J Med. 106: 179184.
  • 13
    Topiramate (Topamax). (2003) Physician's Desk Reference. Medical Economics Co., Inc: Montvale, NJ. pp 25012507.
  • 14
    Shank, R. P., Gardocki, J. F., Streeter, A. J., Maryanoff, BE. (2000) An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 41(Suppl 1): S3S9.
  • 15
    Richard, D., Picard, F., Lemieux, C., Lalonde, J., Samson, P., Deshaies, Y. (2002) The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord. 26: 344353.
  • 16
    Bray, G. A., Hollander, P., Klein, S., et al (2003) A 6-month randomized, placebo-controlled, dose-ranging trial for weight loss in obesity. Obes Res. 11: 722733.
  • 17
    Wilding, J., Van, Gaal L, Rissanen, A., Vercruysse, F., Fitchet, M., OBES-002 Study Group. (2004) A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord. 28: 13991410.
  • 18
    Astrup, A., Caterson, I., Zelissen, P., et al, OBES-004 Study Group. (2004) Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res. 12: 16581669.
  • 19
    Finer, N., James, W. P., Kopelman, P. G., Lean, M. E., Williams, G. (2000) One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 24: 306313.
  • 20
    Wirth, A., Krause, J. (2001) Long-term weight loss with sibutramine: a randomized controlled trial. JAMA. 286: 13311339.
  • 21
    Hill, J. O., Hauptman, J., Anderson, J. W., et al (1999) Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 69: 11081116.
  • 22
    Whelton, P. K., Appel, L. J., Espeland, M. A., et al, TONE Collaborative Research Group. (1998) Sodium reduction and weight loss in the treatment of hypertension in older adults: a randomized controlled trial of nonpharmacological interventions in the elderly (TONE). JAMA. 279: 839846.